Stock Analysis
Blau Farmacêutica Second Quarter 2024 Earnings: Beats Expectations
Blau Farmacêutica (BVMF:BLAU3) Second Quarter 2024 Results
Key Financial Results
- Revenue: R$465.1m (up 28% from 2Q 2023).
- Net income: R$48.7m (down 31% from 2Q 2023).
- Profit margin: 11% (down from 19% in 2Q 2023). The decrease in margin was driven by higher expenses.
- EPS: R$0.28 (down from R$0.40 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Blau Farmacêutica Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 24%.
Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Global Biotechs industry.
Performance of the market in Brazil.
The company's shares are up 11% from a week ago.
Risk Analysis
Before you take the next step you should know about the 3 warning signs for Blau Farmacêutica that we have uncovered.
Valuation is complex, but we're here to simplify it.
Discover if Blau Farmacêutica might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BOVESPA:BLAU3
Blau Farmacêutica
A pharmaceutical company provides high-complpexity drugs in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States.